• Exelixis Inc., of South San Francisco, reported preliminary data from a Phase Ib drug interaction trial of cabozantinib in renal cell carcinoma, showing a high rate of durable tumor response, with a low rate of primary refractoriness to drug therapy, and a long median progression-free survival.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter